NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis $21.76 -0.37 (-1.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.80 +0.04 (+0.21%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tourmaline Bio Stock (NASDAQ:TRML) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tourmaline Bio alerts:Sign Up Key Stats Today's Range$21.16▼$22.3450-Day Range$15.32▼$23.3452-Week Range$11.56▼$29.79Volume226,846 shsAverage Volume188,810 shsMarket Capitalization$558.80 millionP/E RatioN/ADividend YieldN/APrice Target$49.33Consensus RatingBuy Company Overview Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Read More Tourmaline Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreTRML MarketRank™: Tourmaline Bio scored higher than 31% of companies evaluated by MarketBeat, and ranked 766th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTourmaline Bio has only been the subject of 2 research reports in the past 90 days.Read more about Tourmaline Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tourmaline Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.39% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 2.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.39% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 2.38%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.37 News SentimentTourmaline Bio has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.Search Interest6 people have searched for TRML on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tourmaline Bio's insider trading history. Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Stock News HeadlinesBMO Capital Remains a Buy on Tourmaline Bio (TRML)July 30 at 5:22 AM | theglobeandmail.comTourmaline Bio Inc News (TRML) - Investing.comJuly 3, 2025 | investing.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)TRML - Tourmaline Bio Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMTRML - Tourmaline Bio Inc Executives - MorningstarJune 24, 2025 | morningstar.comMTourmaline Bio Elects Directors and Ratifies AuditorJune 6, 2025 | tipranks.comH.C. Wainwright maintains $50 target on Tourmaline Bio stockMay 29, 2025 | uk.investing.comH.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 ResultsMay 29, 2025 | msn.comSee More Headlines TRML Stock Analysis - Frequently Asked Questions How have TRML shares performed this year? Tourmaline Bio's stock was trading at $20.28 on January 1st, 2025. Since then, TRML stock has increased by 7.3% and is now trading at $21.76. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) issued its quarterly earnings results on Friday, May, 2nd. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.02. Who are Tourmaline Bio's major shareholders? Tourmaline Bio's top institutional investors include Wesbanco Bank Inc. (0.10%), Y Intercept Hong Kong Ltd (0.09%) and AlphaQuest LLC (0.01%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara, Aaron Kantoff and Sandeep Chidambar Kulkarni. View institutional ownership trends. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tourmaline Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings5/02/2025Today8/01/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Price Target for Tourmaline Bio$49.33 High Price Target$70.00 Low Price Target$25.00 Potential Upside/Downside+123.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.75% Return on Assets-26.11% Debt Debt-to-Equity RatioN/A Current Ratio33.87 Quick Ratio33.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.71 per share Price / Book1.88Miscellaneous Outstanding Shares25,680,000Free Float22,346,000Market Cap$566.24 million OptionableOptionable Beta2.00 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:TRML) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.